Abstract. Overall survival improvement in patients with metastatic breast cancer is still the principal treatment target in this patient group. Chemotherapy is an essential component of the combination treatment for patients with breast cancer. Until recently female patients with a disease progression developed after several lines of drug therapy were deemed to have an unfavorable prognosis. Patients with locally recurrent or advanced breast cancer having tumors with overexpression of the HER2 gene also belong to the group of patients with unfavorable prognosis.The efficiency of eribulin in combination with trastuzumab as the first line chemotherapy for patients with disease progression observed not more than 12 months after completion of neo/adjuvant chemotherapy was studied in Phase II Study in female patients with HER2-positive breast cancer. Eribulin as the first line therapy for patients with HER2-positive metastatic breast cancer ensured 71.2% of objective response rate and progression-free survival (PFS) median 11.6 months. This combination is characterized by an acceptable safety profile corresponding to that of eribulin and trastuzumab and may be an option of choice as the first line therapy for patients with HER2-positive metastatic breast cancer.
Key words: HER2-positive phenotype of breast cancer, metastatic HER2-positive breast cancer, eribulin, taxanes, anthracyclines, life expectancy, overall survival.
For citation: Gaysina E.A. Potential for improving survival in patients with metastatic breast cancer. Clinical Observation. (Oncology Bulletin of the Volga Region, 2016, №3 (25), P. )
Multidisciplinary Clinical Medical Centre «Medical City», Tyumen
Gaysina E.A. ― head of therapeutic services for therapy of the Multidisciplinary Clinical Medical Centre «Medical City»
32 Barnaulskaya Str., Tyumen, Russian Federation, 625041, e-mail: firstname.lastname@example.org